AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Stars over Athens: The who’s who at Calcalist's first Israel-Greece conference
2
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
3
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"
More news

Teva

20 stories about Teva
חברת ה תרופות טבע Teva

Teva Makes Headway in European Copaxone Patent Case

01.04.19|Lilach Baumer
Generic 40 mg versions of the drugmaker's blockbuster drug for multiple sclerosis have been available in Europe since late 2017, but Teva is now making strides in court
מפעל טבע הר חוצבים ירושלים

Bidder Contests Teva Sale of Jerusalem Facility

31.03.19|Amitai Gazit and Lilach Baumer
Earlier this month, Teva agreed to sell the land tenure rights of its two Jerusalem factories, set to close by the end of 2019, for a combined $77 million
מטה טבע פתח תקווה

Teva Settles Patent Litigation Case for Blood Sugar Stabilizer With Novo Nordisk

24.03.19|CTech
Under the settlement agreement, Teva will be able to sell a generic version of the drug as of 2023
מפעל חברת טבע הר חוצבים ירושלים

Teva Selling Jerusalem Land Tenure Rights Ahead of Factory Closures

20.03.19|Golan Hazani
Teva currently has two manufacturing plants in Jerusalem, both slated for closure by the end of 2019
נסיעת בכורה של רכבת מהירה מ ירושלים ל תל אביב

Copaxone-Competitor Developer Mapi Pharma Gets Funding for Jerusalem Plant

19.03.19|Lilach Baumer
The clinical-stage company develops more efficient versions of existing successful drugs, including a long-acting version of Teva's multiple sclerosis cash cow
דוד לוסטיג סמנכ"ל בכיר מנהל התפעול טבע ישראל

Senior Vice President David Lustig Leaving Teva After 25 Years

19.03.19|Tzally Greenberg
Lustig will be replaced by Miran Denac, currently senior vice president and cluster manager for central and Western Europe operations
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Morgan Stanley Downgrades Teva From Overweight to Equal Weight

07.03.19|Hezi Sternlicht
The bank upgraded Teva to overweight in November, setting a target price of $27, at the time a 20% premium on the company’s trading price
קאר שולץ מנכל טבע

Teva’s Schultz is Running Out of Rope

14.02.19|Hezi Sternlicht
In the fourth quarter and annual earnings reported by the company Wednesday, Teva missed analyst consensus for non-GAAP earnings per share, and shareholders seem to be losing patience
מנכ"ל טבע החדש קור שולץ 2

Teva to Close 11 More Manufacturing Facilities in 2019

14.02.19|Lilach Baumer
The drugmaker published its fourth quarter and annual reports Wednesday, dropping almost 8% on NYSE after forecasting a steep cut in profits for 2019
קאר שולץ מנכל טבע

Teva Falls in Pre-Market Following Low-Profit Forecasts for 2019

13.02.19|Lilach Baumer
The drugmaker forecasts revenues of $17 billion to 17.4 billion for 2019, much lower than analyst expectations
מפעל טבע קריית שמונה

Teva to Sell Northern Israeli Facility to Private Equity Fund FIMI

06.02.19|Tzally Greenberg
Teva unveiled a reorganization plan in December 2017 to ameliorate its debilitating debt, announcing its intention to close or sale facilities and layoff 25% of employees by 2019
הפגנה מפגינים פיטורים טבע אשדוד

Teva Signs Deal to Sell Closed Israeli Factory

03.02.19|Lilach Baumer
In December 2017, Teva announced plans to sell or close many of its manufacturing facilities and let 25% of global employees go as part of a debt management plan
מנכ"ל טבע החדש קור שולץ 2

CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports

27.01.19|Lilach Baumer
In October, American prescription benefits management company Express Scripts added Amgen and Eli Lilly’s drugs to its coverage but excluded Teva
קאר שולץ מנכל טבע

Israel Tax Authority to Demand Over NIS One Billion From Teva

16.01.19|Omri Milman and Tomer Ganon
Teva did not pay taxes in Israel for the decade preceding 2014, saving NIS 20.6 billion in tax benefits
מפעל טבע קריית שמונה

Teva Settles 14-Year Medicaid Pricing Fraud Lawsuit in Illinois

13.01.19|Lilach Baumer
The Israeli drugmaker agreed to pay $135 million to bring the allegations to rest. 46 other pharmaceutical companies were also named in the suit
מנכ"ל טבע החדש קור שולץ 2

Copaxone Profit will Continue to Fall, But Teva is Set to Double Down on Biosimilars

08.01.19|Lilach Baumer and Hezi Sternlicht
Speaking at J.P. Morgan’s Healthcare Conference on Monday, CEO Kåre Schultz said he expects the U.S. generic market to stabilize in 2019
הפגנת עובדי טבע מול ביתה של גליה מאור

Teva Restructuring Cuts Deep into Israel’s Pharma Job Market, Exports

07.01.19|Amitay Gazit and Dror Reich
Israel's pharmaceutical export fell 21% in 2018, according to a new report. Teva let go around 1,200 Israeli employees last year
חברת ה תרופות טבע Teva

Teva Agrees to Stop Selling Amgen Generic Following Patent Infringement Settlement

03.01.19|Lilach Baumer
In December, Teva reached a confidential settlement and licensing agreement with drug manufacturer Neos Therapeutics, regarding its generic version for Neos' ADHD drug
מטה טבע פתח תקווה

Teva Reaches Confidential Patent Settlement with Neos

27.12.18|CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026
פפרצי מטה טבע בפתח תקווה

Teva Chooses New Israeli Headquarters in Tel Aviv

16.12.18|Micky Grunfeld and Tzally Greenberg
The company will relocate from Petah Tikva, 8 kilometers east of Tel Aviv, to northeastern Tel Aviv neighborhood Ramat HaHayal in mid-2020
Previous ArticlesMore Articles